24.3 C
New York
Wednesday, June 3, 2026

Tag: Sex

newssourceFORcompanyinformationcontent1marketreleases

AbbVie Announces European Commission Approval of AQUIPTA® (atogepant) for the Acute Treatment of Migraine in Adults

AQUIPTA® (atogepant) is now approved in the European Union for the acute treatment of migraine in adults, with or without aura, and for the...

Eik fasteignafélag hf.: Árshlutauppgjör fyrir fyrstu sex mánuði ársins 2025

Árshlutareikningur Eikar fasteignafélags hf. fyrir tímabilið 1. janúar til 30. júní 2025 var samþykktur af stjórn og forstjóra félagsins þann 13. ágúst 2025.

REVEALING STUDY HAS REJUVANT LEADING THE LONGEVITY PACK

Renowned Longevity Researcher Reveals Highlights of New Study to NBJ Conference Guests FERNANDINA BEACH, Fla., Aug. 11, 2025 /PRNewswire/ -- Dr. Brian Kennedy, one of...

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease

Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global Phase III trials to demonstrate statistically significant reduction in...

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease  

Ad hoc announcement pursuant to Art. 53 LR

Eik fasteignafélag hf.: Birting uppgjörs fyrstu sex mánaða ársins 2025 þann 13. ágúst – Kynningarfundur 14. ágúst

Eik fasteignafélag hf. mun birta uppgjör fyrir fyrstu sex mánuði ársins 2025 eftir lokun markaða miðvikudaginn 13. ágúst n.k. Kynningarfundur verður haldinn á skrifstofu félagsins við Smáratorg 3, 18. hæð, 14. ágúst n.k. klukkan 8:30. Hreiðar Már Hermannsson, forstjóri og Lýður H. Gunnarsson, framkvæmdastjóri fjármálasviðs, munu kynna uppgjörið og svara spurningum að lokinni kynningu. Boðið verður upp á léttan morgunverð frá klukkan 8:00.

NexZen Extracts Broadens Best THCA Flower Collection with Premium Indoor-Grown Strains

NexZen Extracts Expands Indoor-Grown THCA Flower Lineup with 11 New Strains 
NexZen Extracts Expands Indoor-Grown THCA Flower Lineup with 11 New Strains

NX Taiwan Awarded Healthy Workplace Certification by “Ministry of Health and Welfare”

- Received High Praise for Promoting Health Management and Contributing to Local Communities - TOKYO, Aug. 4, 2025 /PRNewswire/ -- Nippon Express (Taiwan) Co., Ltd....

NexZen Extracts Expands THCA Flower Collection with New Strains in 2025

NexZen Extracts, a premium name in hemp-derived cannabinoid products, has been officially recognized as the Choice of THCA flower brand of 2025 
NexZen Extracts, a premium name in hemp-derived cannabinoid products, has been officially recognized as the Choice of THCA flower brand of 2025

Ignored and Undiagnosed: Sleep Apnea Threatens Women’s Cognitive Health

Alzheimer's disease affects more than 6 million Americans, and emerging research identifies Obstructive Sleep Apnea (OSA) as a significant, modifiable risk factor. Interrupted breathing...

EISAI TO PRESENT FOUR-YEAR EFFICACY AND SAFETY DATA ON CONTINUOUS TREATMENT WITH LECANEMAB AT THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE 2025

Latest findings from Eisai's robust Alzheimer's disease (AD) pipeline include results from lecanemab long-term data, an immunoassay for measuring amyloid-β protofibrils in cerebrospinal fluid,...

UPDATE – Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference – The Sildenafil Cream That Raises the Bar

A first-of-its-kind solution for women’s arousal - the same active ingredient as in Viagra® for men - in a proprietary topical formulation demonstrated to work where women need it most

Tevogen.AI Receives International Patent Publication for AI Technology Predicting Immunologically Active Peptides

WARREN, N.J., July 18, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) announced today that the International Bureau of the World Intellectual Property Organization (WIPO) has published its international patent application (Publication No. WO 2025/129197) titled, "Systems and Methods for Predicting Immunologically Active Peptides with Machine Learning Models."

Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025

- Presentations highlight clinically meaningful reductions in BMI in patients with acquired hypothalamic obesity –

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsSex

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers